Clinical description FSHD families

F1
The proband presented at age 28 with right arm weakness. He was, however, aware of shoulder weakness since age 18. Examination showed mild asymmetric facial weakness, asymmetrical shoulder muscle weakness and atrophy and abdominal muscle weakness.
His 62 year old father, noted shoulder muscle weakness since age 16, and pelvic girdle weakness since age 30. He was diagnosed as FSHD on clinical grounds. His parents, four brothers, two sisters and one daughter were reportedly unaffected.
Examination showed mild asymmetric shoulder girdle weakness (Shoulder abduction: Right 110, Left 80), severe pelvic girdle and hamstrings weakness, and Right tibialis anterior paralysis and Left paresis.
F2
The proband, a 61-year-old woman, noticed right foot dorsiflexor weakness at age 17. At age of 20, she noticed difficulty lifting her arms above shoulder level.
Presently, she can walk small distances but is otherwise wheelchair dependent.
Examination shows very mild orbicularis oculi weakness and moderate orbicularis oris weakness. She has bilateral scapular winging with severe biceps and triceps weakness, moderate wrist extension weakness, moderate to severe hip girdle weakness and bilateral foot drop.
Her 32 year old son had onset of foot dorsiflexor weakness at age 18 followed by shoulder girdle weakness at age 20. Examination showed moderate facial weakness, Lemmers et al 3 and bilateral scapular winging. He had mild triceps and finger extension weakness in the upper extremities and normal lower extremity strength except asymmetric tibialis anterior weakness.
F3
The proband, a 47 years-old woman, developed progressive facial and shoulder girdle muscle weakness starting at age 15. At age 45, she noticed difficulty in walking and climbing stairs and was diagnosed clinically with FSHD. Her 26 yearsold older daughter had asymmetric facial and shoulder girdle involvement (R. arm abduction 80°, L. arm 70°) and right foot dorsiflexor weakness highly evocative of FSHD.
F4
The proband was noted to have dysarthria and facial weakness at age two.
Examination at age 5, showed severe facial weakness, scapular winging, as well as abdominal, quadriceps and hamstring weakness.
His father, aged 37 has right facial weakness since childhood. Examination showed facial weakness as well as right scapular winging with shoulder girdle weakness, asymmetric pectoralis major atrophy and abdominal muscle weakness.
F5
This family is an example of a FSHD family in which the deletion of D4Z4 extends proximally and was described in Lemmers et al. (S4) .
F6
Family F6 consists of a deceased affected father who has six children, of whom four sons are affected and have been examined. Two children and fourteen grandchildren have not been examined. The proband (66 years old) reported a drop-foot at the age of 18 and was noted to have facial and shoulder muscle weakness on clinical examination. He became aware of significant upper-arm weakness at the age of 45 and pelvic girdle weakness at 50 years and noticed a weak handgrip at 62 years when he started wearing foot-ankle orthoses.
Although the four brothers differed in age by 8 years, they all had a comparable clinical condition on a recent physical examination.
F7
Family F7 has been reported before (Rf207 in (S5)). The proband had mild facial weakness, moderate shoulder girdle weakness and mild foot-extensor weakness when he was examined for the first time at the age of 49. Her eldest daughter had mild facial, shoulder and foot-extensor weakness in addition to Klippel-TrenaunayWeber syndrome. Her sister had mild facial and shoulder girdle weakness. The proband's brother (55 years) complained of inability to run, what he related to low back pain. His oldest son (29 years) had mild shoulder weakness, another son (321; 20 years) had asymmetrical facial weakness, and one daughter (324; 18 years) had mild facial and shoulder-girdle weakness.
F8
The proband, aged 64 had symptom onset at age 25 with proximal leg weakness.
Exam shows facial weakness, scapular winging, mild biceps and hip flexion weakness, and asymmetric tibialis anterior weakness. Her twin daughters have FSHD. In one, symptom onset was at age 30 with difficulty raising her right arm.
Examination at age 45, shows facial weakness, scapular winging, severe biceps weakness and asymmetric wrist extension weakness, and mild quadriceps tibialis anterior weakness as well as abdominal muscle weakness. Her twin sister dates her symptoms to age 18 with difficulty lifting her arm. Exam at age 45 shows facial weakness, scapular winging, severe biceps weakness, mild triceps weakness, mild hip girdle, tibialis anterior and abdominal weakness.
Detailed genotyping D4Z4 locus
For the genotyping high quality DNA was isolated from peripheral blood lymphocytes. The genotyping (chromosomal variation) was based on the chromosomal location (chromosome 4q or 10q), the SSLP variation, the array size and composition (sensitivity to restriction enzymes BlnI and XapI) of the D4Z4 repeat array and on the distal variation A and B (1). In short, restriction enzyme digested genomic DNA was separated by PFGE and after Southern blotting analyzed with different radioactive labelled DNA probes. The SSLP size variation was determined by PCR. All methods have been described previously and can by found on the Fields Center Website (www.fieldscenter.org).
Sequence analysis of the proximal D4Z4 sequence (D4F104S1D4Z4 region) and distal D4Z4 sequence (D4Z4 and pLAM or D4Z4 and 4qB) All primers for proximal and distal D4Z4 PCR were designed using Primer3 software and optimal PCR results were obtained when using high quality plug DNA prepared for PFGE analysis (1) that was, after equilibration in TE -4 , dissolved in TE -4 to a final DNA concentration of 25 ng/uL.
The sequence of the D4F104S1-D4Z4 region ( Fig. 1B; A, A-L and B chromosomes, nucleotides 4309-7854 in Genbank accession number AF117653) of different chromosomes was determined with either forward primer 5′-CTG GGA GTT GGG CAT TTT CTc ATT AGC-3′ or forward primer 5′-CTG GGA GTT GGG CAT TTT CTg ATT AGC-3′ in combination with reverse primer 5′-GGC GGT CTG GGA TCC GGT GA-3′. To enable a PCR reaction that was specifically amplifying a single chromosome 4q we selected individuals that carry the chromosome of interest in combination with a hybrid chromosome 4. Hybrid chromosomes 4 (with normal-sized D4Z4 array) can be found in about 10% of the population. In these individuals all undesirable chromosomes (homologous 4q and 10q) can be eliminated from PCR amplification by a preceding BlnI digestion in which the BlnI restriction site is exclusively absent from the chromosome of interest. In addition some D4F104S1-D4Z4 sequences were determined in the somatic cell hybrids and DNA clones described above. The PCR reaction was performed on 100 ng of genomic DNA with 1.5 uL GC-dNTPs (0.5 mM dATP, 0.5 mM dCTP, 0.5 mM dTTP, 0.3 mM dGTP and 0.2 mM 7-deaza-dGTP), 0.4 U of Phusion F530-L DNA polymerase and supplemented GC buffer, in a total volume of 25 µl. The PCR conditions consisted of an initial denaturation step at 98°C for 3 min., followed by 39 cycles of denaturation at 98°C for 25 s, annealing at 68°C for 20 s, and extension at 72°C for 3 min. The final extension time was 6 min. at 72°C. To determine the sequence consensus for chromosomes 4A161, 4A161L, 4B163, 4B168 and 10A166 at least 3 independent chromosomes of each variant were sequenced.
To obtain D4Z4-pLAM sequences for different 4q and 10q chromosomes we analyzed individuals that carry different combinations of A and B chromosomes. For example, we selected an individual with one 4qA, one 4qB and two BlnI sensitive 10q chromosomes and used A-specific reverse primers in combination a BlnI digestion prior to the PCR amplification to specifically amplify the 4qA chromosome.
The same primers were used to amplify different 10q chromosomes in individuals with two 4qB chromosomes. To amplify the D4Z4-pLAM sequence of 4qA and 10q chromosomes ( TTT GGT TTC AG-3' and reverse primer 5'-CAG GGG ATA TTG TGA CAT ATC TCT GCA CTC ATC-3'. All PCR reactions were performed on 100 ng of genomic DNA, in a solution containing 1.5 uL GC-dNTPs (0.5 mM dATP, 0.5 mM dCTP, 0.5 mM dTTP, 0.3 mM dGTP and 0.2 mM 7-deaza-dGTP, 2.5 U of LA-Taq DNA polymerase and supplemented with 2xGC buffer (TAKARA), with a total volume of 25 µl. The PCR conditions consisted of an initial denaturation step at 94°C for 1 min., followed by 34 cycles of denaturation at 94°C for 30 s, annealing at 68°C for 30 s, and extension at 72°C for 3 min. The final extension time was 10 min. at 72°C. To determine the sequence consensus for chromosomes 4A161, 4A161L, 4B163, 4B168, 10A166 and 10A176T at least 3 independent chromosomes for each variant were sequenced.
Site directed mutagenesis poly(A) signals
Site directed mutagenesis of the poly(A) signals (PAS) were performed using PCR and mismatched primers. For the construction of the 10A166 mutated PAS on the 4A161 construct (generation 4A161b 10mPAS ) PCR products were created with forward primer 5'-GCT GGA AGC ACC CCT CAG CGA GGA A-3' and PAS 10 reverse primer 5'-GGA TCC ACA GGG AGG GGG AAT TTT GAT ATA TCT CTG AAC TAA TC-3' (fragment 1) and with PAS 10 forward primer 5'-GAT TAG TTC AGA GAT ATA TCA AAA TTC CCC CTC CCT GTG GAT CC-3' and M13-Reverse Primer (fragment 2).
Similarly, for the construction of the 4A161 PAS on the 10A166 and 10A176T construct (generation 10A166b 4PAS and 10A176T 4PAS ) PCR products were created with forward primer 5'-GCT GGA AGC ACC CCT CAG CGA GGA A-3' and with PAS 4 reverse primer 5'-GGA TCC ACA GGG AGG GGG CAT TTT AAT ATA TCT CTG AAC TAA TC-3' (fragment 1) and with PAS 4 forward primer 5'-GAT TAG TTC AGA GAT ATA TTA AAA TGC CCC CTC CCT GTG GAT CC-3' and M13-Reverse Primer (fragment 2).
After gel purification PCR fragments 1 and 2 were mixed and amplified with forward primer 5'-GCT GGA AGC ACC CCT CAG CGA GGA A-3' and M13-Reverse primer creating a 1 kb D4Z4-pLAM-pCR2.1 fragment. The PCR reaction was performed on 100 ng of plasmid DNA with 3 uL dNTPs (2 mM), 0.4 U of Phusion F530-L DNA polymerase and supplemented GC buffer (fragment1) or HF buffer (fragment 2), in a total volume of 30 µl. The PCR conditions consisted of an initial denaturation step at 98°C for 3 min., followed by 20 cycles of denaturation at 98°C for 25 s, annealing at 55°C for 30 s, and extension at 72°C for 45 s (fragment 1 and 1 kb D4Z4-pLAMpCR2.1 fragment) or 15 s (fragment 2). The final extension time was 10 min. at 72°C.
Finally, with a KpnI digestion the original Poly(A) signals were replaced by the mutated ones. All constructs were sequence-verified.
Cloning of proximal and distal D4Z4 sequences.
Proximal and distal D4Z4 fragments were cloned in either the TOPO blunt-II (for Phusion amplified fragments) or in the TOPO TA pCR2.1 (for LA-Taq amplified fragments) vector and subsequently these vectors were transfected into NEB 5-alpha F´I q Competent E. coli cells (New England Biolabs).
C2C12 mouse muscle cells were cultured in DMEM supplemented with 20% fetal bovine serum, 4 mM L-glutamine, 4.5 g/L glucose and 1% penicillin-streptomycin in an incubator with 10% CO2 atmosphere at 37°C. For transfection 8x10 4 cells were seeded in each well of a 6-well cell culture plate (Nunc) and grown for 24 hours prior to transfection. To monitor the transfection efficiency D4Z4 plasmids were cotransfected with pEGFP-C1 plasmids. For each construct 2 ug of D4Z4 plasmid DNA was mixed with 2 ug of pEGFP-C1 plasmid DNA after which 365 µl sera-free DMEM was added and 9 µl Plus reagent (Invitrogen). The DNA-Plus Reagent mixture was incubated for 15 minutes at room temperature. Meanwhile 365 µl sera-free DMEM was prepared with 9 µl Lipofectamine reagent (Invitrogen). Then, DNA-Plus reagent mixture and Lipofectamine reagent were combined and incubated for 15 minutes at room temperature to subsequently replace the C2C12 medium for 1 hour in an incubator at 37°C. Afterwards, transfection medium was replaced by 2 mL fresh C2C12 medium and after 24 hour incubation cells were harvested.
Quantification of DUX4 mRNA levels using realtime RTPCR
Total RNA was extracted using the Macherey Nagel total RNA isolation kit with DnaseI treatment. The RNA concentration was determined on a ND-1000 spectrophotometer (Thermo Scientific, Wilmington, USA) and the quality was AGA TGC AAA TC-3' (DAS). All the primers used for real-time PCR were designed using Primer 3 software. To ensure that residual genomic DNA was not being amplified, control experiments were performed in which reverse transcriptase was omitted during cDNA synthesis. Amplification efficiencies were determined from standard curves generated by serial dilution of plasmid DNA.
Northern blot analysis
For the Northern blot analysis of the D4Z4 transcript the previously described C2C12 transfection was scaled up to two 10-cm-diameter Petri dishes per D4Z4 construct. Total RNA was extracted using the Macherey Nagel total RNA isolation kit with DnaseI treatment. For each lane 10 ug total RNA was separated on a 0.8% agarose gel containing 10% formaldehyde and blotted onto Hybond XL (GE healthcare Life Science). Hybridizations were performed in a formamide hybridization mix (S6) for 16 h at 50°C using a 32 P labelled a D4Z4 probe that covers the 300 bp homeobox region of D4Z4 (D4Z4-HD). As control, the transfection efficiency for the different conditions was analyzed by hybridization with a GFP probe. Probe labelling was performed using the Megaprime labeling kit (GE healthcare Life Science) according to the manufacturer's protocol. The blots were washed at 65°C and to a stringency of 2× SSC and 0.1% SDS. The radioactivity on the membranes was visualized by phosphor imaging on a Storm 840 Phosphor Imaging System (Molecular Dynamics).
DUX4 expression analysis in primary myotubes
Myoblasts were isolated from a needle muscle biopsy sample of the Vastus Lateralis as described before (S7). After pre-plating, myoblasts were cultured in F-10 Nutrient medium (Gibco Invitrogen, Carlsbad, U.S.A.), 20% FCS, 100U/ml penicillin and 100μg/ml streptomycin, 4pg/ml bFGF and 1μM hexamethazone, in a humidified atmosphere containing 5% CO 2 at 37°C.
Myotubes were obtained by growing the myoblasts at 70% confluency on differentiation media (DMEM (+glucose, +L-glutamin, +pyruvate), 2% horse serum) for 6 days. Total RNA isolation, cDNA preparation and real-time PCR were performed as described in the previous sections All samples were run in duplo. All PCR products were analyzed for specificity by melting curve analysis and on a 2% agarose gel. The results of the quantitative RT-PCR were analyzed and quantified using iQ5 optical system software version 2.0 (Biorad Laboratories, Veenendaal, The Netherlands). All expression levels were calculated using GAPDH (primers hGAPDHFw 5'-AGC ACA TCG CTC AGA CAC-3' and hGAPDHRev 5'-GCC CAA TAC GAC CAA ATC C-3') as constitutively expressed standard for cDNA input, and the relative steady-state RNA levels of the DUX4 gene (forward primer 5'-CCC AGG TAC CAG CAG ACC-3' and reverse primers 5'-TCC AGG AGA TGT AAC TCT AAT CCA-3' (PAS)) were calculated by the method of Pfaffl (S8) .
3' RACE
The polyadenylation site was identified by 3' RACE using the GeneRacer kit (Invitrogen) according to manufacturer's instructions. Total RNA (1 µg) from C2C12 transfected cells was treated with amplification grade DNase I followed by clean-up on RNeasy column (Invitrogen). Reverse transcription was performed using the GeneRaceroligodT primer and Superscript III, followed by treatment with RNase H.
DUX4 transcripts were amplified by nested PCR using forward primers LS 182 5'-CAC TCC CCT GCG GCC TGC TGC TGG ATG A-3' then 1A 5'-GAG CTC CTG GCG AGC
CCG GAG TTT CTG-3' combined with the GeneRacer 3' primer and then GeneRacer 3' nested primer. PCR conditions were 95°C denaturation for 30 seconds, 62°C annealing for 30 seconds and 68°C extension for 1 minute. Primary and nested reactions were each 35 cycles.
In silico prediction of poly(A) signals
For the in silico prediction of poly(A) signals we use the online available tools DNAFSminer (http://dnafsminer.bic.nus.edu.sg/) and PolyApred (http://www.imtech.res.in/raghava/polyapred/). We used accession numbers FJ439133 (4A161) and AL732375 (10A166). 
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